Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses Study Involving VEGF-Targeted…
Browsing: Immunotherapy
Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Making Immunotherapy Work Better For Kidney Cancer. At the Seventeenth…
Edward Copelan, MD, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses Molecular Profiling Of Patients. At…
Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses Clinical Studies Examining…
Frederick Locke, MD, Program Co-Leader, Immunology Moffitt Cancer Center, discusses Improvements To Turn Around Time With CAR-T Therapies. At The…
David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses Thoughts On The Daratumamab Studies. At The…
Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of…
Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, discusses The Development Of LCAR-B38M. At The 60th ASH Annual Meeting…
Julie Vose, MD Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Management Of Common…
Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center, discusses Will CAR-T Therapies Be Expanded Into Solid Tumors. At The…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Aaron Gerds, M.D., M.S. assistant professor of medicine in the Hematology and Medical Oncology department at the Cleveland Clinic Taussig…
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage…
David Peereboom, M.D., Cleveland Clinic Discusses The Future Of Treating Glioblastoma. At ESMO Oncology Conference – Munich, Germany On October…
David Peereboom, M.D., Cleveland Clinic Discusses SL-701 Availability. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.
David Peereboom, M.D., Cleveland Clinic Discusses New Plans With SL-701 Drug. At ESMO Oncology Conference – Munich, Germany On October…
David Peereboom, M.D., Cleveland Clinic Discusses How SL-701 Was Generated. At ESMO Oncology Conference – Munich, Germany On October 19,…
David Peereboom, MD, Cleveland Clinic Discusses SL-701 Phase Two Trial Study Results. At ESMO Oncology Conference – Munich, Germany On…
As chimeric antigen receptor (CAR) T-cell therapies are patient-specific, this novel treatment type poses unique challenges. From the British Oncology…
VXM01 is an orally-administered vaccine that elicits a systemic T-cell response targeting VEGFR-2. Here, Wolfgang Wick, MD, from the German…
One of the major downsides to immunotherapy is its high cost. In this interview, Rafael Fonseca, MD, of the Mayo…
Immunotherapy has been making rapid advancements as of late, especially the area of CAR T-cell therapy. Howard Burris, MD, FACP,…
Patients with metastatic Merkel cell carcinoma (MCC) that does not respond to chemotherapy have a very poor survival rate after…
In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks about prostvac, a novel…
In this interview, Paul Nghiem, MD, PhD, from the University of Washington, Seattle, WA, discusses the results of the Phase…
In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks to us about the…
David I. Quinn, MD, explains his thoughts on 2nd line therapy options following I-O failure 2018 Annual Meeting.
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients…
Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR…
Dr. Jack West summarizes key data from the IMpower131 trial of patients with advanced squamous NSCLC & examines whether the…
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that…
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a…
Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation…
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of…
Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung…
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to…
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to…